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http://www.ro-journal.com/content/7/1/144RESEARCH Open AccessFDG uptake correlates with recurrence and
survival after treatment of unresectable stage III
non-small cell lung cancer with high-dose proton
therapy and chemotherapy
Zuo-Lin Xiang1, Jeremy Erasmus2, Ritsuko Komaki1, James D Cox1 and Joe Y Chang1*Abstract
Background: We studied whether maximum standardized uptake values (SUV) from [18 F] PET/CT predict clinical
outcome after concurrent proton/chemotherapy for stage III non-small cell lung cancer (NSCLC).
Methods: Eighty-four patients were treated prospectively with 74 Gy(RBE) proton therapy and concurrent
chemotherapy. PET/CT scans were available before (SUV1) and within 6 months after (SUV2) treatment. The
predictive value of clinical and PET/CT factors were analyzed with univariate and multivariate Cox regression
models.
Results: Median survival time was 29.9 months. At 3 years, the local recurrence-free survival (LRFS) rate was 34.8%;
distant metastasis-free survival (DMFS), 35.4%; progression-free survival (PFS), 31.2%; and overall survival (OS), 37.2%.
Patients with SUV2 ≥3.6 (the median) had high rates of LR (p= 0.021). Of 12 clinicopathologic features evaluated in
univariate analysis, only KPS, SUV1, and SUV2 predicted LRFS, DMFS, PFS, and OS (p <0.05). Multivariate analysis
showed that KPS (p= 0.025) and SUV2 (p= 0.017) were independently prognostic for LRFS and that SUV1, SUV2, and
KPS were independently prognostic for DMFS, PFS, and OS (p <0.05).
Conclusions: SUV2 predicted LRFS, and SUV1 and SUV2 predicted DMFS, PFS, and OS, in patients with stage III
NSCLC treated with concurrent chemotherapy and high-dose proton therapy.
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Prognostic factorsBackground
Non-small cell lung cancer (NSCLC) is the leading cause
of cancer death worldwide. About one-third of patients
with NSCLC present with locally advanced disease, the
standard treatment for which is concurrent chemoradia-
tion [1]. However, conventional doses of 60 Gy of pho-
ton (x-ray) radiation produce local failure rates of about
50%, and dose escalation has been associated with
increased toxicity, particularly when chemotherapy is
given concurrently with the radiation [1,2]. For some
patients, proton therapy may provide better dose* Correspondence: jychang@mdanderson.org
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reproduction in any medium, provided the ordistributions than photon therapy in that protons allow
delivery of similar or higher doses to malignant tissues
while delivering less radiation to normal tissues, which
could allow safe dose escalation [3,4]. Early results of a
phase II study of high-dose proton therapy involving
doses of 74 Gy(RBE) (assuming a relative biological ef-
fectiveness [RBE] factor of 1.1) given with concurrent
weekly carboplatin and paclitaxel to 44 patients with in-
operable stage III NSCLC indicated favorable toxicity
and promising overall survival compared with published
findings [5]. However, about 20% of these patients
experienced local recurrence and 40% distant recur-
rence. Implementation of individualized therapy would
be greatly facilitated by ways of accurately assessing the
extent of disease, both before treatment (staging) andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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studied intensively for this purpose is 18 F-fluorodeoxy-
glucose positron emission tomography (18 F-FDG PET),
with or without integrated computed tomography (CT).
18 F-FDG PET has been shown to improve the rate of
detection of regional and distant metastases in patients
with NSCLC [6], and 18 F-FDG PET/CT was found to be
more accurate in staging NSCLC than visual correlation
of separate PET and CT images [7]. PET/CT is also
highly accurate for detecting tumor growth and disease
progression in NSCLC after therapy [8]. PET/CT im-
aging can also be useful for delineating radiotherapy tar-
get volumes so that elective nodal irradiation can be
avoided but the dose to PET-avid lesions escalated
[9,10]. PET/CT has been used to predict response to
chemotherapy and to predict clinical outcome in stage
III NSCLC treated with conventional (photon-based)
radiotherapy to 60–63 Gy [11-13]. However, false-
positive findings from therapy-induced inflammation
can be a problem for PET scans obtained after therapy
[14] particularly when higher doses are used.
To date, the potential predictive value of PET/CT for
stage III NSCLC treated with high-dose [74 Gy(RBE)]
radiotherapy combined with concurrent chemotherapy
has not been reported. To address this gap, we sought to
determine whether maximum standardized uptake
values (SUV max) from 18 F-FDG PET/CT and other
clinicopathologic features could predict recurrence and
survival in such patients.
Methods
Study population
All patients included in this analysis had been enrolled
in one of two phase II prospective studies of proton
therapy (clinicaltrials.gov identifiers NCT00495170 and
NCT00991094); both protocols included as a secondary
objective determining the predictive value of PET/CT in
clinical outcomes, and both had been approved by the
institutional review board of MD Anderson Cancer Cen-
ter. For this analysis, 84 patients with unresectable con-
firmed stage III NSCLC were retrospectively identified
based on the availability of pretreatment and posttreat-
ment PET/CT images and SUVs. Patients without
complete PET/CT images and SUVs or those with
images of poor image quality were excluded. Disease in
all cases had been staged with magnetic resonance im-
aging or CT of the brain, CT of the chest, and PET/CT.
Treatment simulation and target volume delineation
Treatment was simulated for all patients with 4-
dimensional (4D) CT to account for tumor motion. The
internal gross tumor volume (iGTV) was defined as the
envelope of motion of the GTV on a reconstructed max-
imum intensity projection image and was verified acrossall phases of the 4D CT dataset [15]. Staging PET/CT
images were fused with 4D CT treatment simulation
images to delineate the gross tumor if the patient’s pos-
ition was the same for the PET/CT and treatment simu-
lation procedures. Otherwise, PET images were used as
a guide to help delineate the GTV. The primary tumor
and clinically positive lymph nodes seen either on the
planning CT scan (>1 cm short axis diameter) or on the
pretreatment PET scan (SUV >3) constituted the GTV.
Any lymph node suspected of harboring disease on
clinical evaluation that was negative on imaging was
subjected to endobranchial sonography or medianoscopy-
based biopsy. An 8-mm isotropic expansion of the iGTV
was added and edited to cover possible microextension
of the tumor or lymph nodes adjacent to gross tumor,
and the resulting volume was defined as the internal clin-
ical target volume. Uninvolved lymph nodes were not
irradiated intentionally.
Radiation doses
The total radiation dose to the tumor target was 74 Gy
(RBE), given in once-daily 2-Gy(RBE) fractions, 5 days
per week, over 7 weeks. Treatment plans were designed
in accordance with previously described dose-volume
constraints [5].
Passive scattering proton therapy planning and adaptive
proton delivery
The iGTV, with the maximum intensity projection dens-
ity from the set of 3-dimensional CT scans used to de-
rive the 4D CT, was used to design compensators and
apertures to account for tumor motion, and the treat-
ment plan was calculated by using the average of the
phases of the 4D CT [3,15-17]. Another set of 4D CT
scans was obtained during week 3 or 4 of treatment (or
as clinically indicated as assessed by the treating phys-
ician) to document tumor shrinkage or other anatomic
or motion-based changes. If the new dose distribution
derived from these changes could not meet the mini-
mum target dose requirement of ≥95% of the prescribed
dose, or if it exceeded normal tissue dose constraints, a
new treatment plan was designed for the remainder of
the treatments.
Chemotherapy
All patients received concurrent carboplatin (2 AUC)
and paclitaxel (50 mg/m2) as weekly intravenous infu-
sions during proton therapy. Neoadjuvant chemotherapy
and adjuvant chemotherapy with carboplatin and pacli-
taxel at systemic doses were allowed.
Evaluation and follow-up
Patients were evaluated weekly during treatment, at
6 weeks after completing proton therapy, every 3 months
Table 1 Clinicopathologic characteristics of 84
unresectable stage III non-small-cell lung cancer patients
Characteristic Patients
Age (y)












NSC NOS 12 (14.3%)
GTV
Median, cm3 (range) 96.6 (4.1-753.2)
SUV1
Median value (range) 14.2 (2.5-66)
Median time, month (range) 0.7 (0.1-2.7)
SUV2
Median value (range) 3.6 (1.9-28.1)
Median time, month (range) 4.2 (0.8-6.0)
Abbreviations: KPS = Karnofsky Performance Status; NSC NOS = non-small cell
cancer and no otherwise specified; GTV = gross tumor volume; SUV =
standardized uptake values.
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up visit included interval medical history and physical
examination, hematologic studies, and CT. Follow-up
PET/CT was required during the first 1–6 months after
treatment and afterward as needed.
Local control at the primary tumor site was evaluated
by serial thoracic CT scans with contrast. If CT scans
showed evidence of recurrent disease, PET or PET/CT
was required and biopsy recommended to confirm re-
currence. Particular attention was paid to patterns of
FDG uptake with respect to radiation field and tumor lo-
cation to avoid confusing inflammation from recurrence;
FDG uptake coincident with the radiation fields extend-
ing beyond the primary tumor boundaries was consid-
ered pneumonitis, not tumor recurrence. All images
were reviewed by diagnostic radiologists and radiation
oncologists specializing in thoracic disease. Unconfirmed
recurrent disease was to be followed up with CT or
PET. The timing of the recurrence was scored as the
time at which the first image (PET and/or CT) showed
abnormalities. Local recurrence was defined as recurrent
disease within the planning target volume (PTV). Nodal
recurrence outside this volume but within the chest or
in the supraclavicular area was documented separately
as regional recurrence.
PET/CT scans
All patients received a median 499.5 MBq (range, 277.5–
740 MBq) intravenous injection of 18 F-FDG before im-
aging, followed by a 60-minute uptake phase. All scans
were obtained with a GE Discovery ST PET/CT scanner,
with vendor-provided software used to interpret image
data. Scans were all acquired in two dimensions at 5
minutes per field of view, and non-contrast CT images
were used for attenuation correction. Patients were to
have fasted for at least 6 hours before the PET scan and
to have a blood glucose level of <150 mg/dL at the time
of injection. Regions of interest were manually drawn on
the transaxial images around the focal 18 F-FDG uptake
zone in the primary tumor, and the SUVmax for each
patient was used to minimize partial-volume effects.
18 F-FDG PET/CT scans were obtained from all patients
before chemoradiotherapy (SUV1, ≤3 months) and after
chemoradiotherapy (SUV2, ≤6 months); delta (Δ) SUV
was SUV1 minus SUV2.
Statistical analysis
Statistical analyses were done with SPSS 16.0 software
(SPSS, Chicago, IL). Medians were used as cutoff values.
Start dates for all survival estimates were the date of
protocol enrollment. Local recurrence–free survival
(LRFS) was defined as the interval from that date to the
date of LR or death; distant metastasis–free survival
(DMFS) from that date to the date of DM or death;progression-free survival (PFS) from that date to the
date of tumor recurrence, DM, progressive disease, or
death; and overall survival (OS) from that date to the
date of death. Cumulative LRFS, DMFS, PFS, and OS
rates were estimated using the Kaplan-Meier method,
and groups of interest were compared by using log-rank
tests. Univariate and multivariate survival analyses were
based on the Cox proportional hazards regression
model. A two-tailed p <0.05 indicated statistical
significance.Results
Characteristics of patients and clinical outcomes
Patient characteristics, including SUVs before and after
treatment, are shown in Table 1. For SUV1, the median
time from PET/CT scan to radiotherapy was 0.7 month
(range 0.1–2.7 months), and median SUV1 was 14.2
(range 2.5–66). For SUV2, the median time from radio-
therapy to follow-up PET/CT scan was 4.2 months
(range 0.8-6.0 months), and median SUV2 was 3.6
(range 1.9–28.1). Median follow-up time for all patients
was 19.2 months (range, 6.1–52.4 months). All patients
Figure 1 Local-regional recurrence–free survival (A) and overall survival (B) curves for all 84 patients.
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weekly chemotherapy, and 22 (26%) also received induc-
tion chemotherapy. Fourteen patients (17%) had LR, but
only 7 (8%) had isolated LR (i.e., LR without RR or DM).
The 2-year local control rate was 83.3%. Three patients
(4%) had regional lymph node recurrence inside the
PTV (i.e., LR). Seven patients (8%) had regional lymph
node recurrence (RR) outside the PTV, but only 2 (2%)
had isolated lymph node recurrence (i.e., RR without LR
or DM). Thirty-three patients (39%) had DM, and 36
patients (43%) had died at the last follow-up. MedianFigure 2 Kaplan-Meier and log-rank analyses of cumulative local recu
before therapy (SUV1; A), after therapy (SUV2; B), the difference betw
was significantly associated with local recurrence.survival time for all patients was 29.9 months. Survival
rates at 3 years were 34.8% (LRFS), 35.4% (DMFS),
31.2% (PFS), and 37.2% (OS). LRFS and OS rates are
shown in Figure 1.
SUV as a prognostic factor
For all 84 patients, censored time-to-event data for LR
and DM were analyzed with the Kaplan-Meier method
and compared with log-rank tests. Patients with SUV2
≥3.6 were found to have higher LR rates (p= 0.021;
Figure 2). Neither SUV1 (p= 0.088) nor ΔSUV (p= 0.670)rrence rates according to standardized uptake values obtained
een SUV1 and SUV2 (ΔSUV; C), and ΔSUV/SUV1 (D). Only SUV2
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median, correlated with LR. Patients with SUV1 ≥14.2
(p= 0.012) and SUV2 ≥3.6 (p= 0.010) had higher rates
of DM, but neither ΔSUV (p= 0.104) nor ΔSUV/SUV1
(p= 0.921) were associated with DM.
Patients with SUV1 ≥14.2 had worse LRFS, DMFS,
PFS, and OS (Figure 3). Patients with SUV2 ≥3.6 had
poorer LRFS, DMFS, PFS, and OS (Figure 4) than those
with SUV2 < 3.6. ΔSUV (dichotomized at the median)
was not related to LRFS (p= 0.405), DMFS (p= 0.229),
PFS (p= 0.151), or OS (p= 0.411). Likewise, ΔSUV/SUV1
(dichotomized at the median) was also not related to
LRFS (p= 0.260), DMFS (p= 0.375), PFS (p= 0.486), or
OS (p= 0.579).
Twelve clinicopathologic features were considered in
the Cox proportional hazards regression univariate ana-
lysis: age, sex, Karnofsky performance status (KPS),
smoking status, tumor histology, GTV, lung V20 , mean
lung dose, SUV1, SUV2, ΔSUV, and ΔSUV/SUV1. Uni-
variate analysis showed that KPS, SUV1, and SUV2 were
associated with LRFS, DMFS, PFS, and OS (Table 2).
Multivariate Cox proportional hazards regression ana-
lyses revealed that KPS (p= 0.025) and SUV2 (p= 0.017)
were independent prognostic factors for LRFS; KPS,Figure 3 Kaplan-Meier analysis of survival rates according to the stan
with SUV1 ≥14.2 worse lower local recurrence–free survival (A), distant me
survival (D) relative to those with SUV1 <14.2.SUV1, and SUV2 were independent prognostic factors
for DMFS, PFS, and OS (Table 2).
For the 22 patients who received induction chemo-
therapy, Cox proportional hazards regression analyses
revealed that neither SUV1 nor SUV2 was associated
with LRFS, DMFS, PFS, or OS (p > 0.30). For the 62
patients who underwent proton therapy with concurrent
chemotherapy only, SUV1 and SUV2 were associated
with DMFS, PFS, and OS (p < 0.05). SUV2 also predicted
LRFS (p= 0.037), which is consistent with the analysis of
all patients as a group.
Discussion
This study confirmed our prior findings that concurrent
chemotherapy and high-dose proton therapy yielded local
control rates in excess of 80% at 2 years and a median OS
time of about 29 months for patients with inoperable stage
III NSCLC [5]. DM remains the dominant pattern of fail-
ure at about 40%. Nodal recurrence outside the PTV (i.e.,
elective nodal failure) occurred in <10% of patients, but
isolated elective nodal failure in only 2%. Our findings
suggest that further escalation of the biological effective
dose, perhaps as hypofractionated radiotherapy, may be
needed in some cases to improve local control; theydardized uptake value obtained before therapy (SUV1). Patients
tastasis–free survival (B), progression-free survival (C), and overall
Figure 4 Kaplan-Meier analysis of survival rates according to the standardized uptake value obtained after therapy (SUV2). Patients
with SUV2 ≥3.6 had worse local recurrence–free survival (A), distant metastasis–free survival (B), progression-free survival (C), and overall survival
(D) relative to those with SUV2 <3.6.
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crucial for reducing DM. The question at this time is how
one might select patients for further dose escalation be-
yond 74 Gy or for more potent chemotherapy [3]. Our
finding that an SUV2 in excess of 3.6 could predict LRFS
(p=0.017) suggests that PET/CT imaging during or to-
ward the end of treatment could be helpful for deciding
whether additional dose escalation is needed and would
allow adequate time to design a boost treatment without
requiring a break in therapy.
Our finding that KPS predicted survival was hardly sur-
prising. Interestingly, however, both SUV1 and SUV2 were
independent prognostic factors for DMFS, PFS, and OS
(p < 0.05). A high SUV1 could be an indicator for higher
dose or novel chemotherapy, given that a high SUV1 pre-
dicted DMFS and OS. This finding is important, because
SUV1 was obtained before the treatment began.
Previously, FDG accumulation before preoperative che-
moradiotherapy was not associated with pathologic out-
come, but FDG uptake by residual tumor masses 2 weeks
after induction chemoradiotherapy predicted pathologic re-
sponse with 88% sensitivity when an SUV cutoff of 3.0 was
used; specificity was only 67% because of treatment-related
inflammation [18]. This finding is consistent with our own.However, the predictive value of SUV1 remains uncertain.
18 F-FDG SUV in the primary tumor before chemora-
diotherapy has been shown to predict local-regional failure
in NSCLC and a high SUV value within the target volume
to correlate with local recurrence [12,19,20]. However, the
radiation dose in those studies was <70 Gy (median, 63 Gy).
In the present study, all patients received 74 Gy(RBE) pro-
ton therapy with chemotherapy, which may have affected
the predictive value of SUV1 before therapy. The p value for
SUV1 and LRFS (p=0.052) was sufficiently close that inclu-
sion of additional patients may demonstrate statistical sig-
nificance; nevertheless, SUV1 did predict disease
progression and DM. Perhaps high-dose proton therapy
with concurrent chemotherapy kills most of the cancer cells
in the target volume but leaves viable, resistant residual cells
that may eventually grow and lead to recurrence. We specu-
late that a higher PET SUV2 value may indicate the re-
growth of such cancer cells. Also, close review of image
patterns with respect to the radiotherapy field can be crucial
for distinguishing local recurrence from radiation-induced
inflammation. Although biopsy can be used to confirm
local-regional recurrence, serial images are often obtained as
a less-invasive alternative. Prospective studies are needed to
clarify the value of SUV2 for predicting LRFS, particularly
Table 2 Univariate and multivariate analyses of factors associated with survival in a cohort of 84 unresectable stage III
non-small-cell lung cancer patients
Variable LRFS DMFS PFS OS
HR 95% CI p HR 95% CI p HR 95%CI p HR 95%CI p
Univariate analyses
Age (< 70 vs≥ 70 years) 0.837,0.425-1.652 0.609 0.820,0.417-1.615 0.566 0.792,0.402-1.560 0.500 0.902,0.456-1.783 0.766
Gender (female vs male) 1.238,0.606-2.532 0.558 1.283,0.628-2.623 0.495 1.253,0.612-2.564 0.538 1.107,0.538-2.275 0.782
KPS (< 90 vs≥ 90) 0.479,0.245-0.938 0.032 0.496,0.253-0.971 0.041 0.509,0.260-0.996 0.049 0.424,0.216-0.831 0.012
Smoking history(Yes vs No) 0.249,0.034-1.822 0.171 0.236,0.032-1.726 0.155 0.260,0.036-1.902 0.185 0.249,0.034-1.822 0.171
Histology (SCCvs Adeno) 0.593,0.287-1.223 0.157 0.556,0.270-1.147 0.112 0.538,0.261-1.111 0.094 0.637,0.309-1.313 0.222
GTV, cm3 (<96.6 vs≥ 96.6) 1.664,0.817-3.309 0.163 1.718,0.855-3.453 0.129 1.734,0.863-3.483 0.122 1.764,0.866-3.592 0.118
Lung V20 (26.2 < vs ≥26.2) 1.057,0.544-2.053 0.871 0.967,0.497-1.881 0.921 1.002,0.515-1.947 0.996 1.005,0.517-1.955 0.989
MLD (1797.1 < vs ≥1797.1) 1.489,0.744-2.979 0.260 1.522,0.767-3.018 0.229 1.528,0.771-3.031 0.225 1.489,0.744-2.979 0.260
SUV1 (< 14.2 vs≥ 14.2) 3.029,1.426-6.432 0.004 3.204,1.504-6.827 0.003 3.269,1.529-6.992 0.002 2.670,1.251-5.699 0.011
SUV2 (< 3.6 vs≥ 3.6) 3.823,1.646-8.881 0.002 3.998,1.718-9.229 0.001 3.877,1.666-9.021 0.002 3.297,1.414-7.686 0.006
ΔSUV (< 9.4 vs≥ 9.4) 1.372,0.649-2.899 0.407 1.575,0.745-3.332 0.235 1.721,0.812-3.646 0.156 1.366,0.646-2.889 0.414
ΔSUV/SUV1 (< 0.68 vs≥ 0.68) 0.652,0.308-1.381 0.264 0.714,0.337-1.511 0.378 0.767,0.363-1.623 0.488 0.807,0.377-1.726 0.580
Multivariate analyses
KPS (< 90 vs≥ 90) 0.409,0.188-0.893 0.025 0.419,0.189-0.929 0.032 0.413,0.187-0.912 0.029 0.291,0.130-0.651 0.003
SUV1 (< 14.2 vs≥ 14.2) 2.304,0.994-5.337 0.052 2.576,1.098-6.041 0.030 2.620,1.115-6.158 0.027 2.347,1.006-5.474 0.048
SUV2 (< 3.6 vs≥ 3.6) 2.947,1.213-7.161 0.017 2.892,1.195-7.001 0.019 2.792,1.155-6.750 0.023 2.620,1.083-6.342 0.033
Abbreviations: LRFS = local recurrence free survival; DMFS = distant metastasis free survival; PFS = progress free survival; OS = overall survival; HR = hazard ration;
CI = confidence interval; KPS = Karnofsky Performance Status; SCC = squamous cell carcinoma; Adeno = adenocarcinoma; GTV = gross tumor volume; MLD =
mean lung dose; SUV = standardized uptake values.
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proton therapy.
We further found that SUV before and after induction
chemotherapy did not predict LRFS, DMFS, PFS, or OS.
This finding could result from the small number of such
patients in our study. However, SUV2 still predicted
LRFS, and SUV1 and SUV2 were still associated with
DMFS, PFS, and OS in the patients who received con-
current chemotherapy and proton therapy without in-
duction chemotherapy.
We did not find an association between ΔSUV or
ΔSUV/SUV1 and survival, although others have shown
such an association among patients with stage III/IV
NSCLC treated with chemotherapy [21,22]. Our study
was limited by its retrospective nature and the relatively
broad interval between completion of therapy and ob-
tainment of the second set of PET/CT images (median
4.2 months, range 0.8–6.0 months). Prospective studies
with PET/CT scans obtained at set times, particularly
during treatment, are needed to validate our observa-
tions and guide further dose escalation.
Conclusions
High-dose PT with concurrent chemotherapy produced
a local control rate of 83.3% on 2 year and median sur-
vival duration of 29.9 months in inoperable stage III
NSCLC. SUV2 predicts LRFS, and both SUV1 and SUV2predict DMFS, PFS, and OS. Because of the limited num-
ber of patients, the results of the present study need to
be further validated in future studies.
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